Pliant Therapeutics Inc
9PT
Company Profile
Business description
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Contact
331 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 481-6770
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
171
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,179.20 | 30.30 | 0.37% |
| CAC 40 | 8,094.20 | 77.27 | -0.95% |
| DAX 40 | 22,999.15 | 288.91 | -1.24% |
| Dow JONES (US) | 41,953.32 | 11.31 | -0.03% |
| FTSE 100 | 8,701.99 | 4.67 | -0.05% |
| HKSE | 23,823.27 | 396.68 | -1.64% |
| NASDAQ | 17,691.63 | 59.16 | -0.33% |
| Nikkei 225 | 37,890.42 | 138.54 | 0.37% |
| NZX 50 Index | 12,163.64 | 108.92 | 0.90% |
| S&P 500 | 5,662.89 | 12.40 | -0.22% |
| S&P/ASX 200 | 7,952.10 | 33.20 | 0.42% |
| SSE Composite Index | 3,386.00 | 22.94 | -0.67% |